Literature DB >> 30132029

The bark giving diabetes therapy some bite: the SGLT inhibitors.

Sally M Marshall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30132029     DOI： 10.1007/s00125-018-4673-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  32 in total

1.  The relation of glycosuria to glycaemia and the determination of the renal threshold for glucose.

Authors:  H P Himsworth
Journal:  Biochem J       Date:  1931       Impact factor: 3.857

2.  Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?

Authors:  Bo Ahrén
Journal:  Diabetologia       Date:  2015-03-20       Impact factor: 10.122

Review 3.  The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.

Authors:  Merlin C Thomas; David Z I Cherney
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 4.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 5.  SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.

Authors:  Christoph Wanner; Nikolaus Marx
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 6.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Diabetologia       Date:  2016-11-22       Impact factor: 10.122

7.  Medications for type 2 diabetes: how will we be treating patients in 50 years?

Authors:  Steven E Kahn; John B Buse
Journal:  Diabetologia       Date:  2015-03-14       Impact factor: 10.122

8.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Authors:  Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici
Journal:  Circulation       Date:  2017-05-18       Impact factor: 29.690

9.  Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.

Authors:  Antonius Baartscheer; Cees A Schumacher; Rob C I Wüst; Jan W T Fiolet; Ger J M Stienen; Ruben Coronel; Coert J Zuurbier
Journal:  Diabetologia       Date:  2016-10-17       Impact factor: 10.122

10.  Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.

Authors:  Laween Uthman; Antonius Baartscheer; Boris Bleijlevens; Cees A Schumacher; Jan W T Fiolet; Anneke Koeman; Milena Jancev; Markus W Hollmann; Nina C Weber; Ruben Coronel; Coert J Zuurbier
Journal:  Diabetologia       Date:  2017-12-02       Impact factor: 10.122
View more
  1 in total

Review 1.  Nonalcoholic Fatty Liver Disease.

Authors:  Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben
Journal:  Handb Exp Pharmacol       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.